Page 11 of 29
PACE - manuscript for review
and had longer hospital LOS (25 ± 6 vs 17 ± 9 days, p=0.0001) compared to those who were COVID- and developed an atrial tachyarrhythmia.
Hemodynamic compromise occurred in 18 participants in the COVID+ group and none in the COVID- group (p=0.0001). Among the 18 COVID+ individuals who experienced hemodynamic compromise, 17 experienced an increasing NE Eq requirement and 1 required immediate direct current cardioversion for hemodynamic instability at atrial tachyarrhythmia onset. In the 17 participants that had an increase in vasopressor requirement, the average change in NE Eq was 0.18 μg/kg/min. A graphical representation of NE Eq dosage changes can be found in Figure 2. atrial tachyarrhythmia was treated with amiodarone in 29 (57%) participants, beta blockers in 38 (75%), calcium channel blocker in 5 (10%), and anticoagulation was felt to be safe in 31 (61%) participants.
Characteristics of participants with new onset atrial tachyarrhythmia by hemodynamic status are shown in Table 4. When compared to the 14 COVID+ hemodynamically stable participants following atrial tachyarrhythmia onset, the 18 COVID+ participants who developed hemodynamic compromise after atrial tachyarrhythmia onset had similar comorbid conditions and baseline echocardiographic assessment with a lower mean arterial pressure (74 ± 16 vs 89 ± 10, p=0.004), higher serum potassium (4.5 ± 0.4 vs 4.2 ± 0.5, p=0.04), greater vasopressor use (83%